Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06309966 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Study acronym: RISE 3
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 114 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 152 to 150v114
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Primary and study completion pushed from May 2026 to Oct 2026
    • Trial sites reduced: 174 → 152 locations
    • Secondary endpoints: 8 to 5
    v113
  3. Study sites: 173 to 174v112
  4. Study sites revised (173)v111
  5. Study sites: 172 to 173v110
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 172 sitesv109
  2. Site details revised at 1 of 172 sitesv108
  3. Study sites revised (172)v107
  4. Site details revised at 1 of 172 sitesv106
  5. Site details revised at 4 of 172 sitesv105
  6. Site details revised at 1 of 172 sitesv104
  7. Site details revised at 1 of 172 sitesv103
  8. Study sites: 171 to 172v102
  9. Site details revised at 1 of 171 sitesv101
  10. Study sites: 169 to 171v100
  11. Study sites: 168 to 169v99
  12. Site details revised at 1 of 168 sitesv98
  13. Study sites: 167 to 168v97
  14. Study sites: 166 to 167v96
  15. Study sites: 165 to 166v95
  16. Study sites: 160 to 165v94
  17. Primary completion date: Jan 2026 to May 2026
    • Study completion date: Feb 2026 to May 2026
    v93
  18. Site details revised at 1 of 160 sitesv92
  19. Study sites: 158 to 160v91
  20. Study sites: 156 to 158v90
  21. Study sites: 152 to 156v89
  22. Site details revised at 2 of 152 sitesv88
  23. Site details revised at 6 of 152 sitesv87
  24. Site details revised at 1 of 152 sitesv86
  25. Study sites: 143 to 152v85
  26. Study sites: 127 to 143v84
  27. Study sites: 116 to 127
    • Primary completion date: Aug 2025 to Jan 2026
    • Study completion date: Sep 2025 to Feb 2026
    v83
  28. Study sites: 114 to 116v82
  29. Site details revised at 3 of 114 sitesv81
  30. Study sites: 110 to 114v80
  31. Study sites: 109 to 110v79
  32. Study sites: 108 to 109v78
  33. Site details revised at 1 of 108 sitesv77
  34. Site details revised at 1 of 108 sitesv76
  35. Site details revised at 1 of 108 sitesv75
  36. Site details revised at 1 of 108 sitesv74
  37. Study sites: 107 to 108v73
  38. Site details revised at 2 of 107 sitesv72
  39. Site details revised at 1 of 107 sitesv71
  40. Site details revised at 1 of 107 sitesv70
  41. Site details revised at 1 of 107 sitesv69
  42. Study sites: 106 to 107v68
  43. Site details revised at 1 of 106 sitesv67
  44. Study sites: 105 to 106v66
  45. Site details revised at 2 of 105 sitesv65
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Trial Details
NCT Number NCT06309966
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 Focal Epilepsy
Related terms Drug Resistant Epilepsy, Epilepsies, Partial, Epilepsy, Seizures
Enrollment 390 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov